Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Behshad Sheldon was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • Apr 15
Egetis Therapeutics AB (publ) Approves Board Appointments Egetis Therapeutics AB (publ) announced at its Annual General Meeting held on April 14, 2026, Jay Donovan Wu and Birgitte Volck were newly elected as members of the Board of Directors. Annonce • Jan 02
Egetis Therapeutics AB (publ)(OM:EGTX) dropped from OMX Nordic Small Cap Index PledPharma AB has been removed from OMX Nordic Small Cap Index . Annonce • Oct 11
Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2026 Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2026. Annonce • Aug 18
Egetis Therapeutics AB (publ) Reports Progress Towards US NDA Submission for Tiratricol Egetis Therapeutics AB (publ) announced that it has submitted a pre-NDA meeting (Type B) request to the US Food and Drug Administration (FDA) to discuss the contents and timing, including the role and position of the ReTRIACt study, of its New Drug Application (NDA) for tiratricol in the US, in light of the Breakthrough Therapy Designation (BTD) awarded on July 15, 2025, by the FDA. A BTD is awarded to programs that have shown preliminary evidence of clinical benefit that results in a meaningful improvement of key signs and symptoms compared to existing therapies. Egetis also provided an update on the recruitment status of the ReTRIACT study (clinicaltrials.gov identifier NCT05579327), evaluating withdrawal of tiratricol in patients with MCT8 deficiency. There are 15 evaluable patients in the trial. The Company plans to initiate the submission of the NDA to the FDA during 2025. The BTD was granted based on the Agency's review of Egetis' detailed analysis of the entire survival data set from the international real-world cohort study by the Erasmus University Medical Center (for preliminary results, see Abstract in Ref. 1), demonstrating a significant and substantial improvement in survival in tiratricol treated vs untreated patients. Receiving a BTD this late in a clinical development program is very encouraging for the forthcoming NDA process, as these designations are typically awarded at an early stage in development. On February 13, 2025, the European Commission approved Emcitate®? (tiratricol) as the first and only treatment for MCT8 deficiency in EU. Egetis launched Emcitate in the first country, Germany, on May 1, 2025. The Company's lead drug candidate Emcitate®? (Tiratricol) is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in at least 16 evaluable patients to verify the results on T3 levels seen in previous clinical trials and publications. As previously communicated, the Company will update the market as soon as recruitment closes, and at that time, the Company will also provide information on when to expect topline results and when the Company plans to submit the NDA application in 2025.iratricol holds FDA Breakthrough Therapy Designation and Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations.iratricol has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor. The drug candidate Aladote®? (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase IIb study has been successfully completed. Annonce • May 07
Egetis Therapeutics AB (Publ) Appoints Margarida Duarte as Members of the Board of Directors Egetis Therapeutics AB (publ) at its AGM held on May 6, 2025 appointed Margarida Duarte as members of the Board of Directors. Annonce • May 05
Egetis Therapeutics AB (Publ) Confirms Launch of Emcitate® in Germany Egetis Therapeutics AB (publ) confirms the availability of its first approved product, Emcitate® (tiratricol) in Germany, as of May 1. This follows the European Commission's approval of Emcitate®? on February 13, 2025 for the treatment of MCT8 deficiency - a rare and serious condition. Emcitate® is the first and only approved treatment in the EU for MCT8 deficiency. The German launch marks a major step in Egetis' journey from an emerging biotech to a commercial-stage company. It is the first of several planned launches in EU with initial focus on the EU4 countries - Germany, France, Spain, and Italy - with pricing and reimbursement dossiers submitted in both Germany and France. Since acquiring the rights to Emcitate, Egetis has made significant scientific, clinical, and manufacturing investments, totaling over EUR 100 million, to advance Emcitate® from concept to commercialization. These include: Clinical Development: Sponsoring two key clinical trials to demonstrate efficacy and safety in patients with MCT8 deficiency and bioavailability /bioequivalence in healthy volunteers, alongside an ongoing pivotal trial supporting the upcoming New Drug Application (NDA) to the US FDA. Non-Clinical Studies: Execution of comprehensive in vivo and in vitro studies to satisfy safety requirements. Formulation Development: Development of a new patient-friendly tablet to meet regulatory requirements and current quality standards. The new tablet also offers greater delivery convenience for patients and caregivers. Manufacturing Upgrades: Major investments in manufacturing infrastructure to meet current Good Manufacturing Practice (GMP) and regulatory standards. Breakeven Date Change • Nov 13
Forecast breakeven date moved forward to 2025 The 5 analysts covering Egetis Therapeutics previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 3.5% to 2024. The company is expected to make a profit of kr4.04m in 2025. Average annual earnings growth of 110% is required to achieve expected profit on schedule. Reported Earnings • Nov 10
Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.34 loss in 3Q 2023) Third quarter 2024 results: kr0.29 loss per share (improved from kr0.34 loss in 3Q 2023). Revenue: kr9.40m (down 23% from 3Q 2023). Net loss: kr86.2m (flat on 3Q 2023). Revenue is forecast to grow 80% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 18% per year. Annonce • Nov 01
Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2025 Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2025. New Risk • Oct 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr247m). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Annonce • Oct 04
Egetis Therapeutics AB (Publ) Announces Resignation of Peder Walberg from the Board of Directors Egetis Therapeutics AB (publ) announced that Peder Walberg has decided to resign from the Board of Directors with immediate effect, to focus on his role as a major shareholder of the Company. Peder will continue to support the Company in his current operational role as a consultant to the Company. Annonce • Sep 19
Egetis Submits A Patent Application to the United States Patent and Trademark Office for Processes of Preparation of Tiratricol Egetis Therapeutics AB (publ) announced that it has submitted a patent application tothe United States Patent and Trademark Office (USPTO) for "Processes of Preparation" of tiratricol. If granted, this would be a significant patent Egetis has obtained for the investigational drug tiratricol. Tiratricol is an endogenously available metabolite of thyroid hormone, with similar bioactive properties as the active thyroid hormone T3. Tiratricol enters the cell independently of the monocarboxylate transporter 8 (MCT8), bypassing the pathophysiologic defect in MCT8 deficiency. Clinical trials for the use of tiratricol for the treatment of MCT8 deficiency are ongoing and in October 2023 Egetis submitted a marketing authorisation application (MAA) in the EU. Accordingly, new and more efficient synthetic routes leading to tiratricol are needed. The processes and compounds described in the patent application help meet these and other needs. Egetis holds Orphan Drug Designation (ODD) for Emcitate® (tiratricol) for MCT8 deficiency in the US and the EU, which currently provides marketing exclusivities of 7 and 10 years, respectively, from the dates of regulatory approvals. Generally, the exclusivityterm of a new patent is 20 years from the date on which the application for the patent was filed in the United States. Breakeven Date Change • Aug 23 The 5 analysts covering Egetis Therapeutics previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 11% to 2024. The company is expected to make a profit of kr16.3m in 2025. Average annual earnings growth of 106% is required to achieve expected profit on schedule.
Reported Earnings • Aug 23
Second quarter 2024 earnings released: kr0.25 loss per share (vs kr0.32 loss in 2Q 2023) Second quarter 2024 results: kr0.25 loss per share (improved from kr0.32 loss in 2Q 2023). Revenue: kr13.9m (up 136% from 2Q 2023). Net loss: kr71.9m (loss narrowed 9.6% from 2Q 2023). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Annonce • Jun 20
Egetis Therapeutics AB (publ) Announces Topline Results of the Phase 2 Triac Trial II with Emcitate (Tiratricol) for MCT8 Deficiency Egetis announced topline results of the Phase 2 Triac Trial II with Emcitate (tiratricol) for MCT8 deficiency The numerical improvements versus baseline observed on the primary endpoints of neurocognitive development assessed by the GMFM-88 and BSID-III scales did not show a statistically significant improvement versus historical controls. The trial confirmed the significant and durable reduction of endogenous T3 concentrations in all patients and the well-tolerated safety profile of tiratricol seen in previous clinical studies, despite higher dosing per kg body weight compared to previous trials. The trial is complementary to the data already submitted and validated in the Marketing Authorisation Application for Emcitate (Tiratricol) for treatment of MCT8 deficiency, based on the benefit of normalization of thyrotoxicosis which has been demonstrated in patients of all ages, as agreed with the European Medicines Agency (EMA). Results from Triac Trial II will be included in the response to EMA 120-day list of questions in August 2024. The forthcoming New Drug Application in the USA will also be based on the already observed treatment effects on T3 concentrations and the manifestations of chronic thyrotoxicosis together with results from the ongoing ReTRIACt trial, as acknowledged by the US Food and Drug Administration (FDA). The timeline for regulatory review and approval in EU remain unchanged. For the US, as previously communicated, the Company will update the market with regards to timelines for NDA submission as soon as 16 evaluable patients have concluded the ongoing ReTRIACT trial. Another important feature of this disease is the high serum T3 concentrations in the blood. This results in thyrotoxicosis in tissues that are not dependent on MCT8 for their thyroid hormone supply. As a result, patients with MCT8 deficiency have clinical features of thyrotoxicosis such as low body weight, elevated heart rate and reduced muscle mass. Preclinical studies have shown that the T3 analogue tiratricol is transported into cells in an MCT8-independent manner. In animal models mimicking MCT8 deficiency, tiratricol has been shown to normalize brain development if administrated during early postnatal life. In previous studies (Triac Trial I and a long-term real-life study) has shown highly significant and clinically relevant results on Emcitate serum thyroid hormone T3 levels and secondary clinical endpoints. Emcitate submitted a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (MA) in October 2023. After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in 16 evaluable patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis will update the market as soon as recruitment has been completed and at that point inform about the timing of availability of top-line results, and the expected timing of the subsequent NDA filing. Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. The drug candidate Aladote®? (calmangafodipir) is a first in class drug candidate developed to reduce the risk of acute liver injury. Reported Earnings • May 03
First quarter 2024 earnings released: kr0.26 loss per share (vs kr0.31 loss in 1Q 2023) First quarter 2024 results: kr0.26 loss per share. Revenue: kr12.1m (up 78% from 1Q 2023). Net loss: kr75.0m (flat on 1Q 2023). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Reported Earnings • Apr 21
Full year 2023 earnings released: kr1.27 loss per share (vs kr1.00 loss in FY 2022) Full year 2023 results: kr1.27 loss per share (further deteriorated from kr1.00 loss in FY 2022). Revenue: kr57.6m (up 155% from FY 2022). Net loss: kr326.9m (loss widened 69% from FY 2022). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 23
Full year 2023 earnings released: kr1.27 loss per share (vs kr1.00 loss in FY 2022) Full year 2023 results: kr1.27 loss per share (further deteriorated from kr1.00 loss in FY 2022). Revenue: kr57.6m (up 155% from FY 2022). Net loss: kr326.9m (loss widened 69% from FY 2022). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Annonce • Dec 13
Egetis Therapeutics AB (publ) Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol (Emcitate) in the USA Egetis Therapeutics AB (publ) provided an update on disease awareness of MCT8 deficiency and the Expanded Access Program (EAP) for tiratricol (for eligible patients with MCT8 deficiency in the USA. MCT8 deficiency is an ultra-rare genetic condition that was described only in 2004 and Egetis is the first pharmaceutical company to develop a possible therapy for this disease. Consequently, the general understanding of the disease and its diagnosis is still very low, even among specialist physicians, and a large proportion of patients remain undiagnosed. The Company has focused its medical affairs activities on improving disease awareness and diagnosis, including participation and dialogues at scientific conferences, patient identification partnerships with genetic testing companies, Key Opinion Leader engagements, advisory boards and interactions with Patient Advocacy Groups. This has resulted in the identification of an additional 50 MCT8 deficiency patients in the USA, previously not diagnosed or known to the Company. Through broad implementation of Expanded Access Program for tiratricol in the USA the administrative burden for treating physicians will be reduced, should they wish to prescribe tiratricol to MCT8 patients under their care. The EAP is also important for patients who finish the ReTRIACt trial, to secure continued access to the treatment. MCT8 deficiency is a severely debilitating ultra-rare disease without any approved treatments and tiratricol has the opportunity to become the first approved treatment of MCT8 deficiency. The EAP was submitted to the US Food and Drug Administration (FDA) in October 2022, on request by the FDA. Healthcare professionals interested in making a request for access to the EAP or learning more about the criteria for the program can visit, study NCT05911399. According to the FDA rules for Early Access Programs, any patient enlisted in an EAP should first be evaluated for participation in ongoing clinical trials. About FDA's Expanded Access program. The Food and Drug Administration (F FDA) regulates the development and approval for marketing of medical products in the USA. Before regulatory approval, it is not normally possible to prescribe a pharmaceutical under development outside of clinical trials. However, in the case of a serious condition or disease for which there are no satisfactory alternatives, and where a clinical trial is not an option for a patient, a physician that wishes to prescribe an unapproved therapy may request permission through FDA's Expanded Access Program (E AP). EAPs are designed to give access to potential therapies before they are approved by the FDA and may include people not typically eligible for clinical trials. Additionally, FDA may ask a sponsor to consolidate expanded access for groups of patients under an existing IND when the agency has received a significant number of requests for individual patient expanded access to an investigational drug for the same use. The Company's lead drug candidate is under development for the treatment of patients with monocarboxylate Emcitate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) has shown highly significant and clinically relevant results on serum thyroid hormone T3 Emcitate levels and secondary clinical endpoints. Egetis submitted a marketing authorisation application (MAA) for to the Emcitate European Medicines Agency (EMA) in October 2023. After a dialogue with the FDA, Egetis is conducting a small randomized, placebo-controlled pivotal study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis intends to submit a new drug application (NDA) in the US for in mid 2024 under the Fast-Track Designation granted by FDA. Emcitate. holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in Emcitate the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Emcitate has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor. This voucher can be transferred and sold to another sponsor. The drug candidate is a first in the US, after approval". This voucher can be transferred or sell to another sponsor. This voucher will be transferred or sold to another sponsors. This voucher can be transferred to another sponsor. The drug candidates. The drug candidate is a priority to another sponsor. This voucher could be transferred to another sponsor. Reported Earnings • Nov 09
Third quarter 2023 earnings released: kr0.34 loss per share (vs kr0.25 loss in 3Q 2022) Third quarter 2023 results: kr0.34 loss per share (further deteriorated from kr0.25 loss in 3Q 2022). Net loss: kr86.2m (loss widened 60% from 3Q 2022). Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Annonce • Nov 08
Egetis Therapeutics AB (publ) to Report Q1, 2024 Results on May 03, 2024 Egetis Therapeutics AB (publ) announced that they will report Q1, 2024 results on May 03, 2024 Annonce • Nov 01
Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024 Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024. Annonce • Oct 27
Egetis Therapeutics AB (publ) Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency Egetis Therapeutics AB (publ) announced that its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Emcitate (tiratricol) for the treatment of MCT8 deficiency has been validated. On October 9, 2023, Egetis announced the submission of the MAA. EMA performs a validation of the applications it receives. The objective is to make sure all essential regulatory elements required for scientific assessment are included in the application prior to the start of the review procedure. The Emcitate MAA is as of October 26, 2023, under review by the Committee for Medicinal Products for Human Use (CHMP). Annonce • Oct 10
Egetis Therapeutics AB (publ) Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency Egetis Therapeutics AB (publ) announced that the Company has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for Emcitate (tiratricol) for the treatment of MCT8 deficiency. This is an important step towards bringing the first approved treatment for MCT8 deficiency to patients and a transformative milestone for the Company. Emcitate has been granted Orphan Drug Designation by the EMA for MCT8 deficiency, and will following approval by the European Commission be eligible for 10 years of market exclusivity within the EU. The median review time for marketing authorisation applications in the EU is around 13-14 months. As agreed with the US FDA, Egetis is conducting a randomized, placebo-controlled pivotal study (ReTRIACt) in 16 evaluable patients to verify the results on thyroid hormone T3 levels seen in previous clinical trials and publications. The study started recruiting in July this year and patient recruitment is proceeding according to plan. Topline results are expected during the first half of 2024 and Egetis intends to submit a new drug application (NDA) in the USA for Emcitate in mid-2024 under the Fast-Track Designation granted by the FDA. In addition to the completed and ongoing clinical trials with Emcitate, more than 180 patients in over 25 countries, are currently being treated with Emcitate as part of the Company's Expanded Access/Named Patient Use/Compassionate Use programs. Annonce • Aug 24
Egetis Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 24, 2024 Egetis Therapeutics AB (publ) announced that they will report fiscal year 2023 results on Feb 24, 2024 Reported Earnings • Aug 23
Second quarter 2023 earnings released: kr0.32 loss per share (vs kr0.17 loss in 2Q 2022) Second quarter 2023 results: kr0.32 loss per share (further deteriorated from kr0.17 loss in 2Q 2022). Net loss: kr79.5m (loss widened 139% from 2Q 2022). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Annonce • Jul 24
Egetis Therapeutics AB (Publ) Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial Egetis Therapeutics AB (publ) announced that the first patient has been included and a second site has been activated in the pivotal ReTRIACt clinical trial for the new drug application (NDA) in the USA for The trial will be conducted across three centers: at Erasmus Medical Center, Rotterdam, the Emcitate. Netherlands, Children's Hospital of Philadelphia, Philadelphia, PA, USA, and Addenbrooke's Hospital, Cambridge, UK. As previously reported, the Company expects topline results from the ReTRIACt study during the first half of 2024 and estimates a subsequent NDA submission in the USA in mid-2024, under the fast-track designation. Breakeven Date Change • Jul 02
Forecast breakeven date pushed back to 2025 The 5 analysts covering Egetis Therapeutics previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 46% per year to 2024. The company is expected to make a profit of kr162.2m in 2025. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Recent Insider Transactions • Jun 02
Director recently bought €85k worth of stock On the 31st of May, Mats Blom bought around 200k shares on-market at roughly €0.43 per share. This transaction amounted to 6.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €86k more in shares than they have sold in the last 12 months. Annonce • May 25
Egetis Terminates Discussions Regarding Potential Acquisition Egetis Therapeutics AB (publ) (OM:EGTX) said on May 23, 2023 Egetis announced termination of discussions regarding potential acquisition of co. Discussions have now been terminated as board believes contemplated offer, terms, while providing premium to current share price, considerably undervalued long-term prospects of company. Breakeven Date Change • May 05
Forecast to breakeven in 2024 The 4 analysts covering Egetis Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr145.6m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule. Reported Earnings • Apr 27
First quarter 2023 earnings released: kr0.31 loss per share (vs kr0.17 loss in 1Q 2022) First quarter 2023 results: kr0.31 loss per share (further deteriorated from kr0.17 loss in 1Q 2022). Net loss: kr74.9m (loss widened 160% from 1Q 2022). Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Breakeven Date Change • Apr 27 The 5 analysts covering Egetis Therapeutics previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr187.1m in 2024. Average annual earnings growth of 0.9% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 13
Forecast breakeven date pushed back to 2025 The 5 analysts covering Egetis Therapeutics previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 11% per year to 2024. The company is expected to make a profit of kr795.2m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule. Reported Earnings • Feb 23
Full year 2022 earnings released: kr1.00 loss per share (vs kr0.63 loss in FY 2021) Full year 2022 results: kr1.00 loss per share (further deteriorated from kr0.63 loss in FY 2021). Net loss: kr193.8m (loss widened 85% from FY 2021). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Annonce • Jan 28
Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023 Egetis Therapeutics AB (publ) announced the recruitment of Katayoun Welin-Berger, PhD, as Vice President Operations effective March 2023. Katayoun will be a member of the Company's leadership team. Katayoun has 30 years of experience in the pharmaceutical, probiotics and dietary supplements industries. She has a broad experience from roles of increasing responsibilities in areas including product development, CMC documentation, GMP manufacturing, procurement, outsourcing, supplier management, divestment, supply chain management and product life-cyclemanagement. Prior to joining Egetis, Katayoun was Vice President Operations at Calliditas Therapeutics with the responsibility of designing and managing the supply chains for development candidates and commercial products, and previously she held a similar role at BioGaia. Katayoun began her career in the pharmaceutical industry at AstraZeneca and held several positions within both R&D and Operations. She obtained a PhD in Pharmacy from Uppsala University. Annonce • Dec 22
Egetis Therapeutics AB (publ) to Report Q1, 2023 Results on Apr 26, 2023 Egetis Therapeutics AB (publ) announced that they will report Q1, 2023 results on Apr 26, 2023 Breakeven Date Change • Nov 16
Forecast to breakeven in 2024 The 4 analysts covering Egetis Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr104.2m in 2024. Average annual earnings growth of 82% is required to achieve expected profit on schedule. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Gunilla Osswald was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 09
Third quarter 2022 earnings released: kr0.25 loss per share (vs kr0.14 loss in 3Q 2021) Third quarter 2022 results: kr0.25 loss per share (further deteriorated from kr0.14 loss in 3Q 2021). Net loss: kr53.9m (loss widened 139% from 3Q 2021). Revenue is forecast to grow 89% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 20
Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.21 loss in 2Q 2021) Second quarter 2022 results: kr0.15 loss per share (up from kr0.21 loss in 2Q 2021). Net loss: kr33.2m (loss narrowed 3.2% from 2Q 2021). Over the next year, revenue is forecast to grow 126%, compared to a 10% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. Breakeven Date Change • Jul 02
Forecast breakeven date pushed back to 2024 The 2 analysts covering Egetis Therapeutics previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr618.0m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule. Breakeven Date Change • May 28
No longer forecast to breakeven The 2 analysts covering Egetis Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr170.0m in 2023. New consensus forecast suggests the company will make a loss of kr44.0m in 2023. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Gunilla Osswald was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 24
Full year 2021 earnings released: kr0.63 loss per share (vs kr2.64 loss in FY 2020) Full year 2021 results: kr0.63 loss per share (up from kr2.64 loss in FY 2020). Net loss: kr104.5m (loss narrowed 41% from FY 2020). Over the next year, revenue is forecast to grow 146%, compared to a 46% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Annonce • Apr 06
Egetis Therapeutics AB (Publ) Announces That the Recruitment Target Has Been Met in the Emcitate® Triac Trial II Study Egetis Therapeutics AB (publ) announced that the recruitment target of 16 patients has been met in the Triac Trial II clinical study with Emcitate® (tiratricol) in patients with MCT8 deficiency. Triac Trial II (clinicaltrials.gov identifier NCT02396459) is an ongoing international, open label, multi-center study in children with MCT8 deficiency, conducted in both Europe and North America, investigating neurocognitive effects of early intervention with Emcitate in very young (<30 months of age) patients. The first patient was dosed in December 2020. The primary endpoint is to evaluate the effects of Emcitate after 96 weeks of treatment as measured by the Gross Motor Function Measure (GMFM)-88 assessment and the Bayley Scales of Infant Development (BSID-III) Gross Motor Skill Domain score. The study will also evaluate the effect of Emcitate on specific motor milestones, such has holding head and sitting independently, as well as the effect on clinical and biochemical thyrotoxic features. The recruitment target of 16 patients has been met in the Triac Trial II clinical study but to include additional patients who has already been identified but not yet screened, the trial will remain open for recruitment a few additional weeks. Results of Triac Trial II are expected in the first quarter of 2024 and are expected to be submitted post-approval to regulatory authorities. Data from preclinical studies suggest that Emcitate restores abnormal neuronal development and myelination in animal models of MCT8 deficiency if given in early postnatal life. In the Triac Trial I study, effects on neurocognitive development were included as exploratory endpoints (in a subset of patients) andthe results indicate a potential for Emcitate to positively influence neurocognitive development when treatment is introduced early, with the largest increase in gross motor function seen in patients where treatment was started before the age of 4 years. Reported Earnings • Feb 18
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: kr0.63 loss per share (up from kr2.66 loss in FY 2020). Net loss: kr104.5m (loss narrowed 42% from FY 2020). Revenue exceeded analyst estimates by 55%. Over the next year, revenue is forecast to grow 50%, compared to a 63% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Annonce • Jan 27
Egetis Therapeutics AB (publ) Secures Conditional Acceptance for Emcitate® as Brand Name in the US Egetis Therapeutics AB (publ) announced that it has received a conditional acceptance from the US Food and Drug Administration (FDA) for the use of the brand name Emcitate® in the US. The company has earlier received the corresponding support from the European Medicines Agency for the use of Emcitate as the brand name in Europe. This is the best possible outcome towards securing a global brand name and the final approval process for the proprietary name Emcitate will be linked to the regulatory submission in the respective markets. Egetis Therapeutics intends to submit a New Drug Application (NDA) in the US for Emcitate for the treatment of monocarboxylate transporter 8 (MCT8) deficiency mid-2023 under the granted Fast Track Designation. Annonce • Jan 19
Egetis Therapeutics AB (publ) Concludes Demonstrating Treatment Effects on T3 Levels in Mct8-Deficiency Could Provide Basis for Marketing Approval for Emcitate® in the Us Egetis Therapeutics AB (publ) announced that in recent regulatory interactions, the US Food and Drug Administration (FDA) acknowledges that demonstrating a treatment effect on thyroid hormone T3 levels and the manifestations of chronic thyrotoxicosis could provide a basis for marketing approval also in the US. Consequently, the Company now has an aligned regulatory strategy for EU and US. The Company intends to submit a New Drug Application (NDA) in the US for Emcitate® (tiratricol) for the treatment of monocarboxylate transporter 8 (MCT8) deficiency in mid-2023 under the Fast Track Designation granted by the FDA in October 2021. This follows the announcement in December 2021 of intention to submit the Marketing Authorisation Application (MAA) for Emcitate to the European Medicines Agency (EMA) based on existing clinical data on the manifestations of chronic thyrotoxicosis in MCT8 deficiency. Data demonstrating significant and clinically relevant effects on T3 and manifestations of chronic thyrotoxicosis in MCT8 deficiency with Emcitate is already available from the Triac Trial I (Groeneweg et al. 2019), as well as a recently published long-term cohort study looking at treatment effects in 67 patients for up to 6 years (van Geest et al. 2021). To complete the clinical package for the US NDA, a randomized controlled study in 16 patients treated with Emcitate will be conducted to verify the results on T3, as demonstrated in the previous trials. Patients will be randomized to continued Emcitate treatment or placebo for 30 days or until meeting a rescue criterion of T3 level above ULN (upper limit of normal), whichever comes first. The primary endpoint of the study is the proportion of patients meeting the rescue criterion within the randomized treatment period. In light of the revised regulatory strategy for submission in US and Europe (as earlier communicated), work is ongoing to confirm the content of the other components of the regulatory dossiers. The Company intends to communicate timelines during first half of 2022 for regulatory submissions of Emcitate globally. The ongoing Triac Trial II will continue to further establish the effects of early intervention on the neurocognitive development aspects of the disease, previously seen in the Triac Trial I. Given the possibility to proceed with regulatory submissions in both EU and US prior to data available from the Triac Trial II and following discussions with regulatory agencies, Egetis will no longer conduct an interim analysis based on 48-week data but will perform the statistical analysis on the complete dataset after the full 96 weeks of treatment making the data more robust. Results are expected in First Quarter 2024 and data from the Triac Trial II is expected to be submitted post-approval to regulatory authorities shortly thereafter. Emcitate holds Orphan Drug Designation (ODD) in both the EU and the US and was granted Rare Pediatric Disease Designation (RPD) in November 2020 and Fast Track designation in October 2021 by the US FDA. Annonce • Jan 12
Egetis Therapeutics AB (Publ) Gets Notice of Intent to Grant for a New European Patent for a Combination Therapy with Aladote Egetis Therapeutics AB (publ) announced that the European Patent Office (EPO) has issued a Notice of Intent to Grant for a new patent covering a combination treatment with the company’s clinical candidate drug Aladote® (calmangafodipir) and N-acetylcysteine ??(NAC). The new patent further improves the unique value proposition of the Aladote franchise and provides patent protection until year 2037 in Europe, before a potential extension. The new patent covers a combination treatment with NAC and Aladote for “late presenters”, i e patients that started treatment with NAC and calmangafodipir 8 hours or later after an overdose of paracetamol. A potential combination product is also covered by the patent. Annonce • Dec 14
Egetis Therapeutics AB (publ) Intends to Submit Marketing Authorisation Application for Emcitate® to the European Medicines Agency Based on Existing Clinical Data Egetis Therapeutics AB (publ) announced that after a pre-submission meeting held last week with concerned European regulatory agencies (EMA's Rapporteur and Co-Rapporteur), the Company concludes that the clinical data from the Triac Trial I (Groeneweg et al. 2019), together with the data from long-term treatment with Emcitate (tiratricol) for up to six years in 67 patients (van Geest et al. 2021) will be sufficient for a regulatory review of a Marketing Authorisation Application (MAA) to the European Medicines Agency for the treatment of monocarboxylate transporter 8 (MCT8) deficiency. Thus, all clinical data necessary for regulatory submission is already available. The ongoing Triac Trial II will continue to further establish the effects of early intervention on the neurocognitive development aspects of the disease. In the light of the revised regulatory strategy for submission in Europe, work is ongoing to confirm the content of the other components of the regulatory dossier. As soon as this work is completed, the Company intends to communicate a firmer timeline for regulatory submission of Emcitate in Europe. Results from Triac Trial I (clinicaltrials.gov identifier NCT02060474) were published in the Lancet Diabetes & Endocrinology in 2019 (Groeneweg et al. 2019), showing clinically relevant and highly significant results on serum T3 concentrations and secondary clinical endpoints following one-year treatment with Emcitate in 46 MCT8 deficiency patients of all ages. The new clinical data published in the Journal of Clinical Endocrinology & Metabolism in October 2021 (van Geest et al. 2021) comes from the investigator-initiated real-life cohort study at 33 sites conducted by the Erasmus Medical Center, Rotterdam, The Netherlands, where the efficacy and safety of Emcitate was investigated in 67 patients with MCT8 deficiency treated with Emcitate (tiratricol) for up to six years. Reported Earnings • Nov 07
Third quarter 2021 earnings released: kr0.14 loss per share (vs kr0.46 loss in 3Q 2020) Third quarter 2021 results: Net loss: kr22.5m (loss narrowed 8.9% from 3Q 2020). Breakeven Date Change • Sep 23
Forecast to breakeven in 2023 The 2 analysts covering Egetis Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr169.8m in 2023. Average annual earnings growth of 87% is required to achieve expected profit on schedule. Annonce • Sep 09
Egetis Receives Approval in Turkey for Compassionate Use of Emcitate® for MCT8 Deficiency Egetis Therapeutics AB announced that it has received approval from the Turkish Medicines Agency for a compassionate use program of its leading candidate drug Emcitate to treat the rare genetic disease MCT8 deficiency. Compassionate use and named patient programs are mechanisms to allow early access to a medicine prior to regulatory marketing approval, granted to pharmaceuticals under development for situations with high unmet medical needs and where no available treatment alternatives exist or are suitable. Compassionate use programs, such as the current Turkish example, need to go through a detailed data review process by the national medicines agencies to become approved. Compassionate use programs are initiated by pharmaceutical companies and allow access to a group of patients in a certain country, when the treating physician considers it appropriate. Outside Turkey, Emcitate is already being supplied on a named patient basis, following individual regulatory approval from the national regulatory agencies, to more than 120 patients in over 20 countries. Reported Earnings • Aug 21
Second quarter 2021 earnings released: kr0.21 loss per share (vs kr0.68 loss in 2Q 2020) Second quarter 2021 results: Net loss: kr34.3m (loss narrowed 5.1% from 2Q 2020). Breakeven Date Change • May 28
No longer forecast to breakeven The 3 analysts covering Egetis Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr170.0m in 2023. New consensus forecast suggests the company will make a loss of kr143.0m in 2023. Recent Insider Transactions • May 15
Insider recently bought €18k worth of stock On the 10th of May, Yilmaz Mahshid bought around 30k shares on-market at roughly €0.60 per share. In the last 3 months, there was an even bigger purchase from another insider worth €19k. Insiders have collectively bought €37k more in shares than they have sold in the last 12 months. Reported Earnings • Apr 24
First quarter 2021 earnings released: kr0.12 loss per share (vs kr0.80 loss in 1Q 2020) First quarter 2021 results: Net loss: kr19.3m (loss narrowed 55% from 1Q 2020). Reported Earnings • Apr 05
Full year 2020 earnings released: kr2.66 loss per share (vs kr1.19 loss in FY 2019) Full year 2020 results: Net loss: kr179.1m (loss widened 192% from FY 2019). Reported Earnings • Feb 19
Full year 2020 earnings released: kr2.66 loss per share (vs kr1.19 loss in FY 2019) Full year 2020 results: Net loss: kr179.1m (loss widened 192% from FY 2019). Products in clinical trials Phase II: 2 Phase III: 1 Analyst Estimate Surprise Post Earnings • Feb 19
Revenue beats expectations Revenue exceeded analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 97%, compared to a 49% growth forecast for the Biotechs industry in Germany. Annonce • Feb 17
Egetis Therapeutics AB (publ) to Report Fiscal Year 2020 Final Results on Mar 30, 2021 Egetis Therapeutics AB (publ) announced that they will report fiscal year 2020 final results on Mar 30, 2021 Annonce • Feb 16
Egetis Therapeutics AB (Publ) Appoints Dr. Kristina Sjöblom Nygren as New Cmo, Effective May 1, 2021 Egetis Therapeutics AB announced that Kristina Sjöblom Nygren, MD, has been appointed Chief Medical Officer (CMO), effective May 1, and will be member of the company's leadership team. The recruitment extends the orphan drug experience and expertise also to the clinical and medical function, further strengthening the company's alignment and strategic focus on this segment. Kristina Sjöblom Nygren is a MD with more than 20 years of experience in the pharmaceutical industry from both large pharmaceutical companies and smaller biotech companies with an extensive experience in late-stage development and regulatory interactions in the rare disease and orphan drug segment in particular. Prior to joining Egetis Therapeutics, Kristina worked as CMO and Head of Development at Santhera, a Swiss pharmaceutical company focusing on developing therapies for rare diseases. Annonce • Jan 22
Egetis Therapeutics Announces Executive Changes Egetis Therapeutics AB (publ) announced that Peder Walberg will assume the role of interim Chief Medical Officer. He replaces Stefan Carlsson who has decided to leave the company to pursue other opportunities. Peder Walberg takes on the position as interim CMO in addition to his current part time role within the company with focus on business development and the continued clinical development of the company’s lead candidate drug, Emcitate®. Peder will also continue as a member of the Board of Directors. Is New 90 Day High Low • Jan 19
New 90-day high: €0.87 The company is up 54% from its price of €0.56 on 21 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. Is New 90 Day High Low • Dec 29
New 90-day high: €0.72 The company is up 44% from its price of €0.50 on 30 September 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Annonce • Dec 16
Pledpharma AB and Solasia Pharma K.K. Announce Results from the Prematurely Closed Pledox®(Sp-04) Polar Program PledPharma AB and Solasia Pharma K.K. announced that PledOx®(SP-04) did not meet the efficacy endpoint in the prematurely closed Phase III POLAR program. Based on further evaluation of the results from the POLAR studies,
the strategic next steps for PledOx will be determined together with Solasia. In the efficacy analysis, based on patient-reported symptoms of moderate or severe CIPN by the validated FACT/GOG-NTx instrument, combining data from both the POLAR-A study and the POLAR-M study, PledOx 5 mol/kg in combination with chemotherapy did not reduce the risk of moderate to severe chemotherapy induced peripheral neuropathy (CIPN) at 9 months after the first cycle of chemotherapy versus chemotherapy alone. The occurrence and type of adverse events observed were generally consistent with the expected toxicity caused by the chemotherapy and the patient populations studied. No negative effect on the anti-cancer effect of chemotherapy were observed with PledOx on progression-free survival (PFS), overall survival (OS) and disease-free survival (DFS), albeit based on a limited number of events. As previously identified by the independent drug safety monitoring board (DSMB) at the time when the POLAR program was prematurely stopped, an increased risk of allergic-hypersensitivity reactions was observed, with a small number of patients experiencing a serious adverse event (SAE) on PledOx in combination with chemotherapy. The severe allergic-hypersensitivity reactions occurred only after repeated treatment cycles. Is New 90 Day High Low • Dec 04
New 90-day high: €0.66 The company is up 33% from its price of €0.49 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Annonce • Nov 25
PledPharma to Be Deleted from Other OTC PledPharma AB (publ)’s Stockholm Ordinary Shares (Sweden) will be deleted from other OTC effective November 24, 2020. The deletion is due to Inactive Security. Reported Earnings • Nov 13
Third quarter 2020 earnings released: kr0.46 loss per share The company reported a soft third quarter result with weaker revenues and control over expenses, though losses reduced. Third quarter 2020 results: Revenue: kr2.57m (down 58% from 3Q 2019). Net loss: kr24.7m (loss narrowed 23% from 3Q 2019). Analyst Estimate Surprise Post Earnings • Nov 13
Revenue misses expectations Revenue missed analyst estimates by 93%. Over the next year, revenue is forecast to grow 73%, compared to a 320% growth forecast for the Biotechs industry in Germany. Annonce • Nov 07
PledPharma AB Appoints Henrik Krook Takes as Vice President Commercial Operations PledPharma AB announced that Henrik Krook takes on the position as Vice President Commercial Operations at PledPharma. The appointment is complementing PledPharma's acquisition of Rare Thyroid Therapeutics (RTT). Henrik will join the company in December. Henrik has a broad experience from over 15 years in commercial leadership settings, including both big pharma and biotechs. He has direct experience in general management, business development, market access, marketing, sales, clinical trials and strategy formulation, including the orphan drug segment, with a track record of developing companies, organizations and assets to ensure continuous value creation. He has previously held different senior corporate and commercial advisory roles for biotech companies such as Affibody and senior managerial positions at e g Alexion, Novartis and Roche. Annonce • Oct 30
PledPharma AB Elects Peder Walberg as New Board Member The extraordinary general meeting of PledPharma AB was held on 28 October 2020, resolved to elect Peder Walberg, CEO and board member in Rare Thyroid Therapeutics International AB, as new board member. Is New 90 Day High Low • Oct 12
New 90-day high: €0.58 The company is up 15% from its price of €0.51 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Annonce • Oct 05
PledPharma AB (OM:PLED) entered into an agreement to acquire Rare Thyroid Therapeutics International AB for approximately SEK 390 million. PledPharma AB (OM:PLED) entered into an agreement to acquire Rare Thyroid Therapeutics International AB for approximately SEK 390 million on October 5, 2020. Out of total consideration, SEK 60 million will be paid in cash and remaining will be paid by issue of 63.773345 new shares in PledPharma. The subscription price for the new shares is SEK 5.25 per share. In addition, the sellers of RTT are entitled to earn out payments based on the future net sales of Emcitate. Earn out will also be payable on sales generated before market approval. Further, the sellers are entitled to an additional earn out in the form of a lump sum payment in an amount corresponding to 50% of the net proceeds in the in the event of a future sale of a potential US Rare Pediatric Disease Priority Review Voucher. The sellers of Rare Thyroid Therapeutics International AB have entered into lock-up undertakings which means that the sellers undertake not to transfer, pledge or otherwise dispose of the Consideration Shares during the applicable lock-up period. For the three largest shareholders in Rare Thyroid Therapeutics International AB (who together own approximately 91% of the shares in Rare Thyroid Therapeutics International AB), the lock-up undertaking applies for 100% of the Consideration Shares during twelve months from the date of the announcement of the outcome of the Rights Issue and for 75% of the Consideration Shares during 24 months from the date of the announcement of the outcome of the Rights Issue. For the minority shareholders in Rare Thyroid Therapeutics International AB the lock-up undertaking applies during three to six months from the date of the announcement of the outcome of the Rights Issue. Cash consideration is funded from own cash-in-hand. PledPharma AB has the intention to change its name to Egetis Therapeutics AB. Rare Thyroid Therapeutics International AB reported net sales of SEK 4 million for the year ended December 31, 2019. The Transaction is based on condition that the general meeting of shareholders PledPharma AB approves the Board of Directors’ of PledPharma's resolutions regarding the issue of consideration shares. An extraordinary general meeting is planned for October 28, 2020. The Transaction is expected to complete in early November 2020. ABG Sundal Collier AB and Pareto Securities AB acted as financial advisors and Advokatfirman Lindahl acted as legal advisor to PledPharma AB. Baker McKenzie acts as legal adviser to ABG Sundal Collier AB and Pareto Securities AB. Annonce • Oct 03
PledPharma AB to Report Q3, 2020 Results on Nov 11, 2020 PledPharma AB announced that they will report Q3, 2020 results on Nov 11, 2020 Annonce • Sep 03
PledPharma AB to Report Fiscal Year 2020 Results on Feb 17, 2021 PledPharma AB announced that they will report fiscal year 2020 results on Feb 17, 2021 
